European Society of Cardiology (ESC) guidelines for acute and chronic
heart failure (HF) includes new recommendations on management of iron
deficiency with Ferinject® (ferric carboxymaltose) in patients with HF
Periodic screening for iron deficiency and the use of Ferinject® to reduce hospitalisation rates and improve HF symptoms are now recommended
In addition, Veltassa®(patiromer)
is newly proposed to enable the use of renin-angiotensin aldosterone
system inhibitor (RAASi) in patients with hyperkalemia
Pharma is pleased to announce that the European Society of Cardiology
(ESC) included new recommendations and proposals in the 2021 ESC
guidelines for the diagnosis and treatment of acute and chronic heart
failure for two of their key products, Ferinject® and Veltassa®.
With regard to iron deficiency, the following new recommendations for HF patients with reduced function of the heart are added:
Periodic screening for iron deficiency is recommended in all HF patients (Class I).
Ferinject® should be considered to reduce the risk of HF hospitalizations in symptomatic HF patients with iron deficiency (Class IIa).
be considered before and early after discharge in patients who have
been hospitalized with acute heart failure and with iron deficiency to
improve HF symptoms and reduce risk of re-hospitalizations (Class IIa).
The existing recommendation to consider Ferinject® in
patients with HF and iron deficiency to alleviate HF symptoms, improve
exercise capacity and quality of life remains unchanged (Class IIa
designation). The results of the AFFIRM-AHF study are reflected in the update of the ESC guidelines. Ferinject® remains the only intravenous (i.v.) iron therapy specifically mentioned in the new ESC HF guidelines.
The guidelines also propose that the use of potassium binder agents like Veltassa® may
allow RAAS inhibitor initiation or uptitration in a larger proportion
of heart failure patients. In patients with chronic or recurrent
hyperkalemia on RAAS inhibitor therapy Veltassa® may
as well be initiated to maintain the patients on guidelines recommended
doses of RAAS inhibitors. The new proposals further describe the unique
evidence for RAASi enabling generated by Veltassa® through the clinical trials.
are very pleased with the new recommendations to the ESC’s guidelines
in heart failure and are grateful for this development for the
patients,” commented Klaus Henning Jensen, Chief Medical Officer of
Vifor Pharma. “With improved diagnosis rates of iron deficiency and
enabling RAASi, more patients can benefit from treatment. Reducing the
risk of heart failure hospitalizations and improving symptoms are key
therapeutic goals in the treatment of heart failure. We are particularly
pleased by the consideration of Ferinject® and Veltassa® in
the new treatment guidelines to achieve these therapeutic goals and
believe this will enable us to further expand our role in helping heart
failure patients with iron deficiency and hyperkalemia live better,
ESC HF guidelines aim to provide practical, evidence-based
recommendations for the diagnosis and treatment of HF, thereby improving
and harmonizing standards of diagnosis and treatment of cardiovascular
diseases for physicians, and potentially optimizing patient care. The
ESC HF guidelines are updated periodically, with the 2021 version
published at the virtual ESC congress end of August 2021.
About Vifor Pharma Group Vifor
Pharma Group is a global pharmaceuticals company. It aims to become the
global leader in iron deficiency, nephrology and cardio-renal
therapies. The company is a partner of choice for pharmaceuticals and
innovative patient-focused solutions. Vifor Pharma Group strives to help
patients around the world with severe and chronic diseases lead better,
healthier lives. The company develops, manufactures and markets
pharmaceutical products for precision patient care. Vifor Pharma Group
holds a leading position in all its core business activities and
consists of the following companies: Vifor Pharma and Vifor Fresenius
Medical Care Renal Pharma (a joint company with Fresenius Medical Care).
Vifor Pharma Group is headquartered in Switzerland, and listed on the
Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
About AFFIRM-AHF The
AFFIRM-AHF study was a multi-center, randomized, double-blind,
placebo-controlled trial, comparing the effect of intravenous ferric
carboxymaltose (FCM) on hospitalizations and mortality in iron deficient
patients admitted for acute heart failure. The study demonstrated that
administration of Ferinject® reduced
the risk of HF hospitalizations and improved quality of life with no
apparent effect on the risk of cardiovascular death.
About Ferinject® Ferinject®/Injectafer® (ferric
carboxymaltose) is a leading i.v. iron therapy with market
authorization in 84 countries by the end of June 2021. More than 16
million patient years of experience have helped to establish Ferinject®/ Injectafer® as a trusted brand, with clinical benefits demonstrated by its efficacy and safety data2.
About Veltassa® Veltassa® (patiromer) is a potassium binder approved for the treatment of hyperkalemia. Veltassa® was
specially designed to exchange calcium rather than sodium for potassium
ions, ensuring suitability for patients who cannot tolerate even small
increases in sodium. Veltassa® should not replace emergency treatment for life-threatening hyperkalemia.
References: 1 Anker,
S.,D. (2018). Effects of ferric carboxymaltose on hospitalisations and
mortality rates in iron-deficient heart failure patients: an individual
patient meta-analysis. Eur J Heart fail. 20(1):125-133. doi:
1002/ejhf.823. 2 Scott Drugs. 2018 Mar;78(4):479–493. doi: 10.1007/ s40265-018-0885-7.